Sec Form 3 Filing - PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC @ Science 37 Holdings, Inc. - 2021-10-06

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC 2. Issuer Name and Ticker or Trading Symbol Science 37 Holdings, Inc. [ SNCE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 929 NORTH FRONT STREET 3. Date of Earliest Transaction (MM/DD/YY) 10/06/2021 (Street) WILMINGTON, NC28401 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 17,314,315 D ( 1 ) ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC 929 NOR TH FRONT STREET WILMINGTON, NC28401 X Wildcat Acquisition Holdings (UK) Ltd 929 NORTH FRONT STREET WILMINGTON, NC28401 X Jaguar Holding Co II 929 NORTH FRONT STREET WILMINGTON, NC X Jaguar Holding Co I, LLC 929 NORTH FRONT STREET WILMINGTON, NC28401 X Eagle Holding Co II, LLC 929 NORTH FRONT STREET WILMINGTON, NC28401 X PPD, Inc. 929 NORTH FRONT STREET WILMINGTON, NC28401 X Signatures Pharmaceutical Product Development, LLC By: /s/ Julia James, Name: Julia James, Title: EVP, General Counsel and Secretary 10/18/2021 Signature of Reporting Person Date Wildcat Acquisition Holdings (UK) Limited By: /s/ B. Judd Hartman, Name: B. Judd Hartman, Title: Director 10/18/2021 Signature of Reporting Person Date Jaguar Holding Company II By: /s/ Julia James, Name: Julia James, Title: General Counsel and Secretary 10/18/2021 Signature of Reporting Person Date Jaguar Holding Company I, LLC By: Eagle Holding Company II, LLC, By: /s/ B. Judd Harman, Name: B. Judd Hartman, Title: General Counsel and Secretary 10/18/2021 Signature of Reporting Person Date Eagle Holding Company II, LLC, By: /s/ B. Judd Harman, Name: B. Judd Hartman, Title: General Counsel and Secretary 10/18/2021 Signature of Reporting Person Date PPD, Inc. By: /s/ Julia James, Name: Julia James, Title: EVP, General Counsel and Secretary 10/18/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. are held of record by Pharmaceutical Product Development, LLC ("Pharma LLC"). Wildcat Acquisition Holdings (UK) Limited ("Wildcat") is the sole member of Pharma LLC; Jaguar Holding Company II ("Jaguar II") is the sole shareholder of Wildcat; Jaguar Holding Company I, LLC ("Jaguar I") is the sole shareholder of Jaguar II; Eagle Holding Company II, LLC ("Eagle II") is the sole member of Jaguar I; and PPD, Inc. is the sole member of Eagle II. By virtue of such relationships, each of the reporting persons may be deemed to have beneficial ownership over such shares of common stock. ( 2 )This report on Form 3 is jointly filed by the reporting persons. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.